Access
To read this story in full you will need to login or make a payment (see right).
Editorial
Nature Medicine 13, 1389 - 1390 (2007)
doi:10.1038/nm1207-1389
Cold shower for AIDS vaccines
Abstract
A vaccine has the potential to substantially reduce the AIDS death toll. In the wake of the recent halting of phase 2b trials of Merck's HIV vaccine candidate, a hard look at the field's expectations and strategies is in order.
Vaccines have helped eliminate or control many public health scourges—smallpox, measles and hepatitis B among them—so it's not unreasonable to think that HIV might be similarly kept in check. Yet in spite of a surfeit of discussion in recent years of the best approach to developing AIDS vaccines, that goal remains out of reach.
To read this story in full you will need to login or make a payment (see right).
